BerGenBio Announces the Establishment of Oncology Scientific Advisory Board PR Newswire BERGEN, Norway, Feb. 2, 2023 - Distinguished global...
BerGenBio reports third quarter 2022 financial results and provides business update PR Newswire BERGEN, Norway, Nov. 15, 2022 - Randomized first...
BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS PR Newswire BERGEN, Norway, Oct. 25, 2022 BERGEN, Norway, Oct. 25...
BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11...
BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS PR Newswire BERGEN...
BerGenBio reports second quarter and half year 2022 financial results and provides business update PR Newswire BERGEN, Norway, Aug. 23, 2022...
BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19 PR Newswire BERGEN, Norway, May 4, 2022 BerGenBio to focus on two...
BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads